You searched for "intravitreal"

559 results found

Corneal Tissue Addition Keratoplasty

Corza Medical has launched a dedicated CTAK (Corneal Tissue Addition Keratoplasty) instrument set, developed in partnership with CorneaGen, to support surgeons performing this approach to keratoconus treatment. CTAK is an intrastromal lamellar keratoplasty procedure using preserved donor corneal tissue, custom...

Clinical relevance of the anatomic classification of neovascular age-related macular degeneration

The author explains why an OCT-based classification of neovascular AMD is needed and how these neovascular subtypes may help to predict patients’ long-term visual outcome. Age-related macular degeneration (AMD) is a chronic and progressive neurodegenerative process involving the macula in...

The management of retinal vein occlusions: a summary

Retinal vein occlusions (RVO) are the most common cause of visual loss from retinal vascular disease second to diabetic retinopathy. Vision is lost due to ischaemia, macular oedema and / or haemorrhage which ultimately effects a patient’s quality of life...

My top five: Emerging alternatives to manage and treat nAMD

Wet (exudative or neovascular) age-related macular degeneration (AMD) is characterised by choroidal neovascularisation, in which new blood vessels from the choroid invade through Bruch’s membrane. These blood vessels proliferate beneath or through the retinal pigment epithelium (RPE), causing patients to...

My Top Five: Emerging alternatives to manage and treat nAMD

Wet (exudative or neovascular) age-related macular degeneration (AMD) is characterised by choroidal neovascularisation, in which new blood vessels from the choroid invade through Bruch’s membrane. These blood vessels proliferate beneath or through the retinal pigment epithelium (RPE), causing patients to...

Emerging therapies for geographic atrophy: complement inhibitors show potential to slow progression and preserve RPE and photoreceptor integrity

Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) characterised by progressive, irreversible loss of the retinal pigment epithelium (RPE) and photoreceptors and is estimated to account for approximately 10% of AMD-related blindness [1-4]. The Age-Related Eye...

Is patient masking leading to an increase in post-op infection after eyelid surgery?

Due to the COVID-19 pandemic, the use of facemasks or face coverings in the clinical setting has become necessary. It is important to recognise that facemasks can be a source of infection after eye surgery and consider ways to minimise...

My Top Five: Promising gene therapies for ocular conditions

Gene therapy, a pivotal advancement in modern medicine, particularly shines in ophthalmology. By targeting defective genes with engineered vectors, this approach promises significant strides in treating inherited retinal diseases. This article reviews the top five gene therapies in late-stage trials,...

My Top Five: Promising gene therapies for ocular conditions

Gene therapy, a pivotal advancement in modern medicine, particularly shines in ophthalmology. By targeting defective genes with engineered vectors, this approach promises significant strides in treating inherited retinal diseases. This article reviews the top five gene therapies in late-stage trials,...

A rare case of endogenous panophthalmitis: Nidus from an E. coli urinary tract infection

Endogenous bacterial endophthalmitis (EBE) is a form of severe inflammation caused by haematogenous spread of a virulent bacterium from a nidus elsewhere in the body to intraocular tissues. It is a rare occurrence and only constitutes around 2–8% of all...

Corneal crosslinking in pellucid marginal degeneration

Fourteen studies were included in this first review examining the use of corneal-crosslinking (CXL) to treat pellucid marginal degeneration (PMD). PMD is a bilateral, non-inflammatory corneal thinning disorder characterised by inferior peripheral corneal thinning 1-3mm from the limbus in the...

The National Treatment Centre-Highland

The National Treatment Centre-Highland opened its doors to patients in April 2023. At a cost of £48 million this represented a significant investment by the Scottish Government for the provision of modern eye care for the North of Scotland.